Search results for: Mikel Berdud
Filter search results
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…recognise data barriers underlying current supply-side estimates, and to be receptive to new approaches. One new approach will be presented in a forthcoming OHE research paper where Berdud, Ferraro and…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
… Citation Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A. (2019). Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in Sweden and the UK: The Case…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…Competition in markets with high epidemiological interest (e.g. Hep C) has been shown to have this effect (Lindgren et al., 2022; Roediger et al., 2019; Berdud et al., 2018). Some…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Share this: Download publication Matthew Napier Brittany Darrow Matthias Hofer Mikel Berdud Amanda Cole Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting…
The Cost of Drug Shortages
16 September 2024
Share this: Download publication Matthew Napier Mikel Berdud Amanda Cole Across the globe, drug shortages are becoming increasingly common. Key takeaways Drug shortages are a growing global concern, affecting multiple…
Our team
…Affairs Tim Watson Director of Marketing and Communications Amanda Cole Director Grace Hampson Director David Mott Associate Director Simon Brassel Associate Director Our economists Mikel Berdud Senior Principal Economist Chris…
A Spotlight on Haemophilia Therapies
3 October 2024
Share this: Download publication Nadine Henderson Matthias Hofer George Bray Dimitrios Kourouklis Mikel Berdud Grace Hampson Pharmaceutical innovation is a key driver of improvements in health outcomes, quality of life…
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
Share this: Download publication Eleanor Bell Mikel Berdud Graham Cookson Sian Hodgson In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…and Equity from Office of Health Economics Modelling the Value of Early Access Schemes and Adaptive Pathway Approaches by Mikel Burdud A range of early access agreements and adaptive…